| Oct 9 |
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
|
| Sep 16 |
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
|
| Sep 10 |
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
|
| Aug 30 |
I-Mab First Half 2024 Earnings: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)
|
| Aug 28 |
I-MAB (IMAB) Q2 2024 Earnings Call Transcript
|
| Aug 28 |
I-Mab Biopharma GAAP EPADS of -$0.09 beats by $0.13
|
| Aug 28 |
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
|
| Aug 27 |
I-Mab Biopharma 1H Earnings Preview
|
| Aug 26 |
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 14 |
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
|
